引用本文:黄东明（综述），冯国生（审校）.分子靶向药物联合治疗EGFR-TKIs继发性耐药肺癌的研究进展[J].中国临床新医学,2016,9(8):748-752.
【打印本页】   【下载PDF全文】   【查看/发表评论】  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被：浏览 1593次   下载 1149次 本文二维码信息
码上扫一扫！
分享到： 微信 更多
字体:加大+|默认|缩小-
分子靶向药物联合治疗EGFR-TKIs继发性耐药肺癌的研究进展
黄东明（综述），冯国生（审校）
530001　南宁，广西中医药大学研究生院（黄东明）；530021　南宁，广西壮族自治区人民医院临床肿瘤中心（冯国生）
摘要:
［摘要］　表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）是晚期非小细胞肺癌EGFR敏感突变患者的一线治疗方案。然而，继发性耐药的出现不可避免。继发性耐药有多种机制，其中以EGFR T790M突变为主要机制之一。目前，靶向药物联合是治疗EGFR-TKIs继发性耐药肺癌的重要策略。该文对其近年研究概况作一综述。
关键词:  非小细胞肺癌  EGFR-TKIs继发性耐药  研究进展
DOI：10.3969/j.issn.1674-3806.2016.08.29
分类号:R 73
基金项目:
Advances of combinations of different molecular targeted drugs in lung cancer secondary resistant to EGFR-TKIs
HUANG Dong-ming, FENG Guo-sheng
Advances of combinations of different molecular targeted drugs in lung cancer secondary resistant to EGFR-TKIs
Abstract:
［Abstract］　EGFR-TKIs is the first-line treatment of EGFR sensitive mutations in patients with advanced non-small cell lung cancer. However, the emergence of acquired drug resistance is inevitable. There are a variety of mechanisms for secondary drug resistance, of which EGFR T790M mutation is one of the main mechanisms. Currently, combinations of different molecular targeted drugs in the treatment of lung cancer secondary resistant to EGFR-TKIs are the important strategies. Their research progress is reviewed in this paper.
Key words:  Non-small cell lung cancer  Secondary drug resistance to EGFR-TKIs  Advanced research